hrp0095fc8.1 | Diabetes and Insulin | ESPE2022

Clinical effectiveness of Liraglutide 3.0 mg for weight management as an adjuvant therapy in obese adolescents with type 1 diabetes: A single-center pilot study

Elbarbary Nancy

Background: Recent data from multiple international registries showed higher rates of overweight and obesity in adolescents with type 1 diabetes (T1DM) compared with their non-diabetic peers. Management of weight gain should be emphasized as obesity is a modifiable cardiovascular risk factor. Liraglutide is a glucagon like peptide‐1 receptor agonist approved for chronic weight management in adolescents with body weight above 60 kg and body mass index (BMI...

hrp0095fc8.2 | Diabetes and Insulin | ESPE2022

Detection of anti-islet antibodies in capillary blood by the antibody detection by agglutination-PCR (ADAP) technology is sensitive and suitable for general population screening programs

Oron Tal , de Jesus Cortez Felipe , Shtaif Biana , Robinson Peter V. , Yackobovitch-Gavan Michal , Seftel David , Phillip Moshe , Tsai Cheng-ting , Gat-Yablonsky Galia

Background: Detection of type 1 diabetes (T1D) at the pre-clinical stage is possible by detecting islet autoantibodies (IA) years before the appearance of symptomatic diabetes. An efficient screening program based on these antibodies will identify children at risk of developing diabetes during childhood. The antibody detection Israeli research (ADIR) is a general population screening program in Israel searching for children with multiple IA who are at risk of ...

hrp0095fc8.3 | Diabetes and Insulin | ESPE2022

Increased zinc alpha2-glycoprotein in patients with type 1 diabetes

Nourbakhsh Mitra , Nourbakhsh Mona , Golpour Pegah , Momeni Hosein , Razzaghy Azar Maryam

Introduction: Zinc α2-glycoprotein (ZAG) is a single-chain polypeptide with molecular weight of 40-kDa, and is secreted from various tissues. It plays several imperative functions in the human body, such as lipid mobilization and immunoregulation. ZAG enhances lipolysis and is involved in reduction of fatty acids in adipose tissues. ZAG has High sequence similarity to MHC-I molecules and is suggested to be a truncated secretory MHC-I–like protein. ...

hrp0095fc8.4 | Diabetes and Insulin | ESPE2022

Unravelling environmental and genetic determinants of glycaemic control in children and young adults with Type 1 Diabetes

Robi Antonietta , Catamo Eulalia , Tinti Davide , Dovc Klemen , Tonno Raffaella Di , Barbi Egidio , Bonfanti Riccardo , Franceschi Roberto , Rabbone Ivana , Battelino Tadej , Tornese Gianluca

Achieving adequate glycaemic control in children with type 1 diabetes (T1D) is essential to reduce incidence and progression of microvascular and macrovascular complications. However, factors that influence glycaemic control remain to be understood. The present study aimed to evaluate clinical, personal, genetic and eating behaviour characteristics underlying glycaemic control in T1D. 325 T1D individuals aged 6 and 20 years and with at least 1 year of disease duration have bee...

hrp0095fc8.5 | Diabetes and Insulin | ESPE2022

Pancreas Unfolded Protein Response is activated in Intrauterine Growth Restriction

Deodati Annalisa , Fausti Francesca , Pampanini Valentina , Cianfarani Stefano

Background: Intrauterine growth restriction (IUGR) is associated with higher risk of cardiometabolic disease. Perturbation of endoplasmic reticulum (ER) homeostasis activates a set of ER-to-nucleus signaling pathways known as unfolded protein response (UPR). We previously showed that IUGR is associated with the activation of hepatic UPR and abnormal glucose profile in male Sprague-Dawley rats. Herein, we report the impact of IUGR on pancreas UPR in the same ex...

hrp0095fc8.6 | Diabetes and Insulin | ESPE2022

Radio-guided surgery using 68Ga-labelled Exendin in patient with congenital hyperinsulinism

Prasad Vikas , Kühnen Peter , Rothe Karin , Hauptmann Kathrin , Boss Marti , Gotthardt Martin , Brenner Winfried , Beindorff Nicola , Blankenstein Oliver

Congenital hyperinsulinism (CHI) is a life-threatening disease and manifests in the majority of cases in the first days after birth. Based on the distribution of affected cells, focal CHI forms are distinguished from diffuse CHI forms. Focal forms occur in most cases due to a paternally inherited heterozygous mutation in a subunit of an ATP sensitive potassium channel (ABCC8, KCNJ11). Within the diagnostic setting, focal forms can be visualized by 18F DOPA PET scan, as a marke...

hrp0095fc9.1 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

COVID-19 and increased prevalence of female precocious puberty in Germany

Sonja Baehr , Dirk Schnabel , Joachim Woelfle , Felix Schreiner , Bettina Gohlke

Background: Several studies observed a positive secular trend for the occurrence of earlier puberty. Genetic background, weight gain, and environmental factors are assumed as contributors. In March 2020, WHO declared a worldwide pandemic of COVID-19. To reduce transmission, Germany and many other countries imposed regulations of social distancing and lockdowns leading to significant changes in daily life for children followed by an increase in obesity but also...

hrp0095fc9.2 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Can pre-treatment BMI influence long-term anthropometric and metabolic outcomes in girls with idiopathic central precocious puberty treated with GnRHa?

Bruzzi Patrizia , Sandoni Marcello , Valeri Lara , Trevisani Viola , Dalla Porta Francesca , Filomena Madeo Simona , Lucaccioni Laura , Predieri Barbara , Iughetti Lorenzo

Background: Gonadotropin releasing hormone analogs (GnRHa) are effective in improving adult height in children with precocious onset of puberty, rapid progression, and good growth potential. In last years, however, some transient metabolic complications have been described during the treatment without the reassurance of long-term data yet. The aim of our study is to clarify if body mass index (BMI) at diagnosis of idiopathic central precocious puberty (iCPP) c...

hrp0095fc9.3 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Therapeutic outcomes in gonadotropin-replaced males with congenital hypogonadotropic hypogonadism (CHH) with identified genetic variants

Rohayem Julia

Background: To delineate testicular responses to gonadotropin replacement in young males with genetically proven CHH.Patients and Methods: In n=72 young males with CHH and at least one variant detected within twenty-four investigated known CHH genes, gonadotropin replacement with hCG and rFSH s.c. was performed over a mean of 2±1 years. Bi-testicular volumes and serum Inhibin B served as baseline parameters, ...

hrp0095fc9.4 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Delayed puberty: unraveling the different trajectories and contributions of AI

Antoniou Maria-Christina , Xu Cheng , Zouaghi Yassine , Papadakis Georgios , Stoppa-Vaucher Sophie , Kolesinska Zofia , Bouthors Thérèse , Lore Ruiz Arana Inge , Elowe-Gruau Eglantine , Phan-Hug Franziska , Pasquier Jerôme , Adamo Michela , Deladoey Johnny , Vuissoz Jean-Marc , Busiah Kanetee , Hauschild Michael , Santoni Federico , Acierno James , Pitteloud Nelly

Introduction: Differentiation between constitutional delay of growth and puberty (CDGP) and congenital hypogonadotropic hypogonadism (CHH) during early adolescence is challenging, as patients exhibit a similar clinical picture and there are no definite clinical or biochemical markers that distinguish these 2 pathologies. A delay in diagnosis, especially for CHH, may have short and long-term health consequences. The aims of this study were: 1) To evaluate the u...